Compare MRVI & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRVI | VSTM |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.8M | 470.7M |
| IPO Year | 2020 | 2011 |
| Metric | MRVI | VSTM |
|---|---|---|
| Price | $3.60 | $6.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $4.57 | ★ $14.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.29 | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $185,743,000.00 | $30,914,000.00 |
| Revenue This Year | $11.80 | $201.42 |
| Revenue Next Year | $7.74 | $263.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $1.67 | $4.01 |
| 52 Week High | $4.11 | $11.25 |
| Indicator | MRVI | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 54.90 | 52.97 |
| Support Level | $3.25 | $5.56 |
| Resistance Level | $3.65 | $6.91 |
| Average True Range (ATR) | 0.18 | 0.33 |
| MACD | 0.06 | 0.11 |
| Stochastic Oscillator | 63.59 | 76.47 |
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.